Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Estcourt, Lise J ^a   Gregg, Richard ^b   Stanworth, Simon ^a   Doree, Carolyn ^a   Trivella, Marialena ^c   Murphy, Michael F ^a   Tinmouth, Alan ^d  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; FIBRINOGEN; FRESH FROZEN PLASMA; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPOIETIN; TRANEXAMIC ACID;

ARTICLE; ARTIFICIAL PLATELET SUBSTITUTE; BLEEDING; CHEMOTHERAPY; HEMATOLOGIC DISEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; THROMBOCYTE POOR PLASMA; THROMBOCYTE TRANSFUSION;

EID: 85031833294     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010982     Document Type: Article

References (86)

1. Barnhart MI, Chen S, Lusher JM. DDAVP: Does the drug have a direct effect on the vessel wall?. Thrombosis Research 1983;31(2):239-52.
2. British Committee for Standards in Haematology (BCSH). Guidelines for the use of platelet transfusions. British Journal of Haematology 2003;122:10-23.
3. British Committee for Standards in Haematology (BCSH). Transfusion guidelines for neonates and older children. British Journal of Haematology 2004;124(4):433-53.
4. Benson AB, Moss M, Silliman CC. Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. British Journal of Haematology 2009;147(4):431-43.
5. Blajchman MA, Slichter SJ, Heddle NM, Murphy MF. New strategies for the optimal use of platelet transfusions. Hematology (American Society of Hematology Education Program) 2008;1:198-204. [DOI: 10.1182/asheducation-2008.1.198].
6. Blumberg N, Spinelli SL, Francis CW, Taubman MB, Phipps RP. The platelet as an immune cell - CD40 ligand and transfusion immune modulation. Immunology Research 2009;45:251-60.
7. The Board of the German Medical Association on the Recommendation of the Scientific Advisory Board. Platelet concentrates. Cross-sectional guidelines for therapy with blood components and plasma derivatives. Transfusion Medicine and Hemotherapy 2009;36:372-82.
8. Bolton-Maggs PHB (Ed) and H Cohen on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2011 Annual SHOT Report. Serious Hazards of Transfusion (SHOT), 2012.
9. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al.Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. Journal of Clinical Oncology 2011;29(4):369-77.
10. Butler C, Doree C, Estcourt LJ, Trivella M, Hopewell S, Brunskill SJ, et al.Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD009072].
11. Cameron B, Rock G, Olberg B, Neurath D. Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion 2007;47(2):206-11.
12. Cancer Research UK. Percentage change in european age-standardised three year average incidence rates, males, UK, 1991-2001 and 2008-2010. Cancer Research UK statistics at http://www.cancerresearchuk.org/cancer-info/cancerstats/ [Accessed 14/02/2013].
13. CDC (Center for Disease Control). United States Cancer Statistics. National Program of Cancer Registries (NPCR) 2012:[Accessed 14/02/2013].
14. Coleman MP, Rachet B, Woods LM, Mitry E, Riga M, Cooper N, et al.Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. British Journal of Cancer 2004;90(7):1367-73.
15. Cook RJ, Heddle NM, Rebulla P, Sigouin CS, Webert KE. Methods for the analysis of bleeding outcomes in randomized trials of platelet transfusion triggers. Transfusion 2004;44:1135-42.
16. De la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A, et al.Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008;111(7):3395-402.
17. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
18. Doshi, N, Orje JN, Molins B, Smith JW, Mitragotri S, Ruggeri ZM. Platelet mimetic particles for targeting thrombi in flowing blood. Advanced Materials 2012;24(28):3864-9.
19. Duke WW. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and coagulation time and report of 3 cases of hemorrhagic disease relieved by transfusion. Journal of the American Medical Association 1910;55:1185-92.
20. Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusions for patients with haematological malignancies: who needs them?. British Journal of Haematology 2011;154(4):425-40.
21. Estcourt LJ, Birchall J, Lowe D, Grant-Casey J, Rowley M, Murphy MF. Platelet transfusions in haematology patients: are we using them appropriately?. Vox Sanguinis 2012;103(4):284-93.
22. Estcourt LJ, Heddle N, Kaufman RM, McCullough J, Murphy MF, Slichter S, et al. On behalf of the BEST (Biomedical Excellence for Safer Transfusion) Collaborative. Differences in the methods of assessing and analysing bleeding outcomes in platelet transfusion trials. Transfusion 2013;53(7):1531-43.
23. Estcourt LJ, Pinchon D, Symington E, Kelly AM, Doree C, Brunskill S, et al.Does bleeding affect patient reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review. Transfusion 2013;[Early on-line publication]. [DOI: 10.1111/trf.12441].
24. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al.Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109(3):944-50. [PUBMED: 17032921].
25. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al.Hematopoietic stem cell transplantation: a global perspective. JAMA 2010;303(16):1617-24. [DOI: 10.1001/jama.2010.491].
26. Greeno E, McCullough J, Weisdorf D. Platelet utilisation and the transfusion trigger: a prospective analysis. Transfusion 2007;72(2):201-5.
27. Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003;43:742-52.
28. Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008;48(7):1447-58.
29. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, et al.A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009;113(7):1564-73.
30. Heddle NM, Webbert K. Investigation of acute transfusion reactions. In: Murphy MF, Pamphilion DH editor(s). Practical Transfusion Medicine. 4th Edition. Blackwell, 2009:63-89.
31. Higby DJ, Cohen E, Holland JF, Sinks L. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion 1974;14:440-5.
32. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
33. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in Statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
34. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
35. Knowles S (Ed), Cohen H, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2010 Annual SHOT Report. Serious Hazards of Transfusion (SHOT), 2011.
36. Koreth R, Weinert C, Weisdorf DJ, Key NS. Measurement of bleeding severity: a critical review. Transfusion 2004;44:605-17.
37. Kuter DJ. Biology and chemistry of thrombopoietic agents. Seminars in Hematology 2010;47(3):243-8.
38. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
39. Manco-Johnson MJ, Dimichele D, Castaman G, Fremann S, Knaub S, Kalina U, et al. Pharmacokinetics and safety of fibrinogen concentrate. Journal of Thrombosis and Haemostasis 2009;7(12):2064-9.
40. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90(7):2515-21.
41. Miao M, Wu DP, Cao XS, Dong WM, Wang B, Ou YJ, et al.Clinical study on platelet engraftment by thrombopoietin in patients with hematological malignancies after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi 2012;33(5):362-5.
42. Murphy S, Litwin S, Herring LM, Koch P, Remischovky J, Donaldson MH, et al.Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology 1982;12:347-56.
43. National Blood Authority. The National Blood Authority's Patient Blood Management Guideline: Module 3 - Medical. National Blood Authority, 2012.
44. NICE. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura TA205. National Institute for Clinical Excellence 2010.
45. NICE. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura TA221. National Institute for Clinical Excellence 2011.
46. Nishiya T, Kainoh M, Murata M, Handa M, Ikeda Y. Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Iba under flow conditions: specific synergy of receptor-ligand interactions. Blood 2002;100(1):136-42.
47. Okamura Y, Fukui Y, Kabata K, Suzuki H, Handa M, Ikeda Y, et al.Novel platelet substitutes: disk-shaped biodegradable nanosheets and their enhanced effects on platelet aggregation. Bioconjugate Chemistry 2009;20:1958-65.
48. Okamura Y, Takeoka S, Eto K, Maekawa I, Fujie T, Maruyama H, et al. Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute. Journal of Thrombosis and Haemostasis 2009;7(3):470-7.
49. ONS. Cancer incidence and mortality tables and charts. Office of National Statistics 2012, issue tcm77-259491:[Accessed 14/02/2013].
50. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
51. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, et al.The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012;47(7):906-23.
52. Patel B, Kirkland K, Szydlo R, Pearce R, Clark R, Craddock C, et al.Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica 2009;94:1399-406.
53. Pavenski K, Rebulla P, Duquesnoy R, Saw CL, Slichter SJ, Tanael S, et al. International Collaboration for Guideline Development, Implementation. Evaluation for Transfusion Therapies, Collaborators. Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2013;Epub:ahead of print. [DOI: 10.1111/trf.12175].
54. Pearce S, Rowe GP, Field SP. Screening of platelet for bacterial contamination at the Welsh Blood Service. Transfusion Medicine 2011;21(1):25-32.
55. Pendry K, Davies T. An audit of use and wastage in the north west of England and North Wales: where have all the platelets gone?. Blood and Transplant Matters 2011;34:17-9.
56. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25:573-7.
57. Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, et al.Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. The Lancet Oncology 10;4:351-69.
58. The Nordic Cochrane Centre. Review Manager (RevMan). 5.2. Copenhagen: The Cochrane Collaboration, 2012.
59. Rysler C, Stoffel N, Buser A, Gratwohl A, Tsakiris DA, Stern M. Effect of beta-blockers, Ca2+antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia. Platelets 2010;21(1):77-83.
60. Sakariassen KS, Cattaneo M, van der Berg A, Ruggeri ZM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984;64:229-36.
61. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, et al.Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology 2001;19:1519-38.
62. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
63. Shehata, N, Tinmouth, A, Naglie, G, Freedman, J, Wilson, K. ABO-identical versus non-identical platelet transfusion: a systematic review. Transfusion 2009;49:2442-53.
64. Silliman CC, Boshkov LK, Mehdizadehkashi Z, Elzi DJ, Dickey WO, Podlosky L, et al.Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003;101(2):454-62.
65. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD005011.pub4].
66. Slichter SJ. Controversies in platelet transfusion therapy. Annual Reviews of Medicine 1980;31:509-40.
67. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al.Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-14.
68. Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology (American Society of Hematology Education Program) 2007:172-8.
69. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, et al.Dose of prophylactic platelet transfusions and prevention of haemorrhage. New England Journal of Medicine 2010;362:600-13.
70. Solomon J, Bofenkamp T, Fahey JL, Chillar RK, Beutler E. Platelet prophylaxis in acute non-lymphoblastic leukemia. The Lancet 1978;1 (8058):267.
71. Solomon C, Pichlmaier U, Schoechl H, Hagl C, Raymondos K, Scheinichen D, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. British Journal of Anaesthesia 2010;104(5):555-62.
72. Sørensen B, Tang M, Larsen OH, Laursen PN, Fenger-Eriksen C, Rea CJ. The role of fibrinogen: a new paradigm in the treatment of coagulopathic bleeding. Thrombosis Research 2011;128(Suppl 1):S13-16.
73. Stanworth SJ, Dyer C, Choo L, Bakrania L, Copplestone A, Llewelyn C, et al.Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews 2010;24(3):163-71.
74. Stanworth SJ, Estcourt LJ, Powter G, Kahan B, Dyer C, Choo L, et al.A no-prophylaxis platelet transfusion strategy for hematologic cancers. New England Journal of Medicine 2013;368(19):1771-80. [PUBMED: WOS:000318540000005].
75. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
76. Taylor C (Ed.), Cohen H, Mold D, Jones H, et al.on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2009 Annual SHOT Report. SHOT Steering Group, 2010.
77. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8(16). [DOI: 10.1186/1745-6215-8-16].
78. Tinmouth AT. Chapter 18: Platelet transfusion, alloimmunization and management of platelet refractoriness. Canadian Blood Services. 4th Edition. Canadian Blood Services, 2007.
79. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. New England Journal of Medicine 1997;337:1861-70.
80. Verma A, Agarwal P. Platelet utilization in the developing world: strategies to optimize platelet transfusion practices. Transfusion and Apheresis Science 2009;41(2):145-9.
81. Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, et al.Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012;380(9850):1309-16.
82. Wardrop D, Estcourt L, Doree C, Hopewell S, Stanworth S, Murphy MF. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD009733.pub2].
83. WHO. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset publication No. 48. Geneva: World Health Organisation, 1979.
84. Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD008235.pub2].
85. Estcourt L, Stanworth SJ, Doree C, Hopewell S, Murphy MF, Tinmouth A, et al.Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3].
86. Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004269.pub2].